Carlisle Companies Inc (CSL)

97.26
0.02 0.02
NYSE : Consumer Goods
Prev Close 97.24
Open 97.16
Day Low/High 97.16 / 97.45
52 Wk Low/High 93.47 / 116.40
Volume 2.68K
Avg Volume 659.20K
Exchange NYSE
Shares Outstanding 64.60M
Market Cap 6.28B
EPS 3.90
P/E Ratio 27.40
Div & Yield 1.40 (1.40%)

Latest News

CSL Behring Receives Orphan-Drug Exclusivity For HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human])

CSL Behring Receives Orphan-Drug Exclusivity For HAEGARDA® (C1 Esterase Inhibitor Subcutaneous [Human])

FDA grants seven-year marketing exclusivity for subcutaneous C1-INH to prevent HAE attacks

10 Sectors That Will Profit Big-Time From Oil's Crash

10 Sectors That Will Profit Big-Time From Oil's Crash

Oil prices are tumbling down. Bad news for companies and petro states, but great news at the pump and for these ten industries...

New Data Demonstrate Prophylactic Treatment With IDELVION® Reduces Bleed Frequency And Has Potential To Positively Impact Patients With Haemophilia B

New Data Demonstrate Prophylactic Treatment With IDELVION® Reduces Bleed Frequency And Has Potential To Positively Impact Patients With Haemophilia B

Findings presented at the International Society on Thrombosis and Haemostasis Congress 2017 show product's impact on treatment adherence, consumption and quality of life

CSL Behring Awards Researchers To Advance Immunoglobulin Therapy In Treating Neurological Disorders

CSL Behring Awards Researchers To Advance Immunoglobulin Therapy In Treating Neurological Disorders

CIDP and Autoimmune Epilepsy Researchers Granted 2017 Interlaken Leadership Awards

New Findings Show AFSTYLA® Provides Long-lasting Efficacy Without Increased Product Consumption For Prophylactic And On-Demand Treatment Of Haemophilia A

New Findings Show AFSTYLA® Provides Long-lasting Efficacy Without Increased Product Consumption For Prophylactic And On-Demand Treatment Of Haemophilia A

Results of study, which compared AFSTYLA to octocog alfa, were presented at the International Society on Thrombosis and Haemostasis Congress 2017

New Data For Two Leading Haemophilia Medicines -- AFSTYLA® And IDELVION® -- To Be Presented At The International Society On Thrombosis And Haemostasis Congress 2017

New Data For Two Leading Haemophilia Medicines -- AFSTYLA® And IDELVION® -- To Be Presented At The International Society On Thrombosis And Haemostasis Congress 2017

New findings demonstrate CSL Behring's promise to develop and deliver innovative treatments that improve patients' lives

Carlisle Companies Acquires Drexel Metals

Carlisle Companies Acquires Drexel Metals

Carlisle Companies Incorporated (NYSE:CSL) today announced the acquisition of Drexel Metals, Inc.

Carlisle Companies To Announce 2nd Quarter Results On July 25, 2017

Carlisle Companies Incorporated (NYSE:CSL) will release second quarter 2017 results on Tuesday, July 25, 2017 after the market closes.

New Innovation In The Fight Against Hemophilia Earns CSL Behring The NORD 2017 Industry Innovation Award

Driven by its promise to save lives and protect people's health, CSL Behring is honoured to be recognized by NORD, a tireless advocate for rare disease patients.

Carlisle Reports First Quarter 2017 Results

Carlisle Companies Incorporated (NYSE:CSL) reported net sales of $857.

Carlisle Companies Declares Regular Quarterly Dividend

The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) has declared a regular quarterly dividend of $0.

Therapeutic Goods Administration Approves AFSTYLA® - CSL Behring's Novel Recombinant Haemophilia A Treatment

- AFSTYLA is the first and only single-chain recombinant factor VIII specifically designed to treat haemophilia A

Improving Access To Lifesaving Treatments For Bleeding Disorders In The Developing World

- CSL Behring Marks World Hemophilia Day by Donating IUs of its Bleeding Disorders Medicines to the World Federation of Hemophilia

Jeffrey Modell Foundation To Open The First North African Network For Primary Immunodeficiencies

CSL Behring Sponsors the First Network of its Kind on the African Continent

CSL Behring Awards Grant To Patient Groups To Develop Innovative Ways To Advocate For Patients

CSL Behring's Local Empowerment for Advocacy Development Grant helps rare disease patient groups and patients protect access to lifesaving therapies.

Jeffrey Modell Foundation To Open The First North African Network For Primary Immunodeficiencies

CSL Behring Sponsors the First Network of its Kind on the African Continent

Carlisle Companies To Announce 1st Quarter Results On April 27, 2017

Carlisle Companies Incorporated (NYSE:CSL) will release first quarter 2017 results on Thursday, April 27, 2017 after the market closes.

New England Journal Of Medicine Publishes Pivotal Phase III Data For CSL Behring's Subcutaneous C1-Esterase Inhibitor In HAE Patients

- Median reduction in hereditary angioedema (HAE) attack rate relative to placebo was 95% at the highest dose studied

Largest Ever CIDP Clinical Study Completed

PATH study evaluated subcutaneous immunoglobulin efficacy and safety for treating Chronic Inflammatory Demyelinating Polyneuropathy

Carlisle Companies Appoints Robert M. Roche Vice President And Chief Financial Officer Effective February 15, 2017

Carlisle Companies Incorporated (NYSE:CSL) is pleased to announce the appointment of Robert M.

Carlisle Reports Fourth Quarter And Full Year 2016 Results

Carlisle Companies Incorporated (NYSE:CSL) reported record net sales of $893.

Carlisle Companies Declares Regular Quarterly Dividend

The Board of Directors of Carlisle Companies Incorporated (NYSE:CSL) has declared a regular quarterly dividend of $0.

Carlisle Companies Acquires Arbo Holdings Limited

Carlisle Companies Incorporated (NYSE:CSL) today announced the acquisition of Arbo Holdings Limited, a leading provider of sealants, coatings and membrane systems used by architects and contractors for waterproofing and...

Short Interest Falls 26% For CSL

Short Interest Falls 26% For CSL

The most recent short interest data has been released for the 12/30/2016 settlement date, which shows a 460,234 share decrease in total short interest for Carlisle Companies Inc. , to 1,303,008, a decrease of 26.10% since 12/15/2016.